View our expert Mathias Kahl, Director Process Development at IDT Biologika, talking about our AAV and LV expertise and how we can help your team to design a seamless and scalable vector-production process.
Learn more about
<LI> How to leverage innovative testing and manufacturing platforms to reduce timelines while increasing cost-savings for viral vector production </LI><LI> About the benefits of partnering with experienced CDMOs with AAV and LVV manufacturing experience</LI><LI> And more </LI>
<b>Part 1</b> – About IDT Biologika / AAV and LV in CGT / Market Situation / Manufacturing concepts for AAV and LV / Challenges
<b>Part 2</b> – Improvements / IDT Biologika Manufacturing Concept / Q&A Session 1
<b>Part 3</b> – Q&A Session 2